MAP2K7 and cardiomyopathy: Altogether, these preclinical studies encourage the use of MEK-inhibitors as a strategy to target vascular pathologies and cardiomyopathy caused by an aberrant activation of the RAS-RAF-MEK-ERK-MAPK pathway.